Evidence map›Paper›PMID 40448826›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages.

Elif Baris, Huseyin Saygin Portakal, Arda Aslan, Zeynep Firtina Karagonlar, Metiner Tosun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elif BarisDepartment of Medical Pharmacology, Faculty of Medicine, Izmir University of Economics, Sakarya Cd. 156, 35330, Izmir, Türkiye. elif.baris@ieu.edu.tr.
Huseyin Saygin PortakalDepartment of Genetics and Bioengineering, Faculty of Engineering, Izmir University of Economics, Izmir, Türkiye.
Arda AslanDepartment of Genetics and Bioengineering, Faculty of Engineering, Izmir University of Economics, Izmir, Türkiye.
Zeynep Firtina KaragonlarDepartment of Genetics and Bioengineering, Faculty of Engineering, Izmir University of Economics, Izmir, Türkiye.
Metiner TosunDepartment of Medical Pharmacology, Faculty of Medicine, Izmir University of Economics, Sakarya Cd. 156, 35330, Izmir, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is well-established for its metabolic benefits, including glycemic control and weight loss. Beyond these roles, it exhibits significant anti-inflammatory properties, though the mechanisms remain underexplored. This study investigates the anti-inflammatory effects of liraglutide in lipopolysaccharide (LPS)-stimulated RAW 264.7 murine macrophages. Results demonstrate that increasing concentrations of liraglutide suppresses LPS-elevated prostaglandin E2 (PGE2), 6-keto prostaglandin F1α (6-keto-PGF

Indexed as

alpha7 Nicotinic Acetylcholine ReceptorAnti-Inflammatory AgentsInflammationLiraglutideMacrophagesProstaglandin-Endoperoxide SynthasesAnimalsLipopolysaccharidesMiceMolecular Docking SimulationRAW 264.7 Cellsalpha7 Nicotinic Acetylcholine ReceptorAnti-Inflammatory AgentsLipopolysaccharidesLiraglutideProstaglandin-Endoperoxide SynthasesCholinergicCyclooxygenaseInflammationIn silico analysisLiraglutideNicotinicProstaglandins

Identifiers

PMID40448826
PMCPMC12552294

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.